Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare Conference in San Francisco. The two ...

It’s not AbbVie’s first foray into T-cell engager dealmaking—the pharma paid $65 million upfront in October to license EvolveImmune’s multispecific biologics for various targets in solid ...

Normunity Inc. has closed a $75 million series B financing to support its pipeline of novel anticancer therapies targeting untapped drug mechanisms. Proceeds from the financing will be used to advance ...

Data from an ongoing phase 1 trial (NCT05997615) showed encouraging preliminary safety and efficacy of the dual-masked prostate-specific membrane antigen (PSMA)-targeting T-cell engager VIR-5500 in ...

in combination with IMDELLTRA ® (tarlatamab), Amgen’s DLL3-targeting Bispecific T-cell Engager (BiTE ®) therapy, in patients with extensive-stage small cell lung cancer (ES-SCLC).

The asset in question is a trispecific T-cell engager developed by WuXi’s multispecific antibody platform WuXiBody. Candid is eyeing getting the candidate into the clinic in the first half of 2026.